These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 35092996)
1. [The discussion of related issues in the efficacy evaluation of COVID-19 vaccine]. Jiang ZW; Xia JL Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jan; 56(1):82-86. PubMed ID: 35092996 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine trials: The use of active controls and non-inferiority studies. Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811 [TBL] [Abstract][Full Text] [Related]
3. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768 [TBL] [Abstract][Full Text] [Related]
5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
6. Considerations on the clinical development of COVID-19 vaccine from trial design perspectives. Jiang Z; Wang X; Xia J Hum Vaccin Immunother; 2021 Mar; 17(3):656-660. PubMed ID: 32991223 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2: Unique Challenges of the Virus and Vaccines. Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900 [TBL] [Abstract][Full Text] [Related]
9. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark. Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115 [TBL] [Abstract][Full Text] [Related]
10. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
11. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries. Nsanzimana S; Gupta A; Uwizihiwe JP; Haggstrom J; Dron L; Arora P; Park JJH Am J Trop Med Hyg; 2021 Jul; 105(3):561-563. PubMed ID: 34270458 [TBL] [Abstract][Full Text] [Related]
13. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
14. Identification of Generalized Peptide Regions for Designing Vaccine Effective for All Significant Mutated Strains of SARS-CoV-2. Biswas S; Manna S; Dey T; Chatterjee S; Dey S Comb Chem High Throughput Screen; 2022; 25(3):414-428. PubMed ID: 34077341 [TBL] [Abstract][Full Text] [Related]
15. Placebo-controlled trials of Covid-19 vaccines - Are they still ethical? Ortiz-Millán G Indian J Med Ethics; 2021; VI(2):1-8. PubMed ID: 33908358 [TBL] [Abstract][Full Text] [Related]
16. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines. Hajissa K; Mussa A Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862 [TBL] [Abstract][Full Text] [Related]